BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35296326)

  • 1. Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant.
    Ranadeva NDK; Sirisena ND; Wetthasinghe TK; Noordeen N; Dissanayake VHW
    BMC Res Notes; 2022 Mar; 15(1):104. PubMed ID: 35296326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
    Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
    Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
    Ismail Al-Khalil W; Al-Salhi L; Rijjal S; Aljamali M; Youssef LA
    BMC Cancer; 2022 Oct; 22(1):1067. PubMed ID: 36243690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
    Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
    Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
    Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
    J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.
    Wang T; Zhou Y; Cao G
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1095-1111. PubMed ID: 33515076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
    Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
    Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Woods B; Veenstra D; Hawkins N
    Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
    Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
    PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.